In osteoclastlike cells. J Cell Physiol 2008, 215(1):47?four. 7. Tonelli M, Pannu N, Manns B: Oral phosphate binders in sufferers with kidney failure. N Engl J Med 2010, 362(14):1312?324. 8. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W: Lanthanum carbonate reduces phosphorus burden in patients with CKD stages three and four: a randomized trial. Clin J Am Soc Nephrol 2009, 4(1):178?85.9.10. 11.12.13.14.15.16. 17.18.19.20.21. 22.23.24.25.26.Helas S, Goettsch C, Schoppet M, Zeitz U, Hempel U, Morawietz H, Kostenuik PJ, Erben RG, Hofbauer LC: Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009, 175(two):473?78. Hofbauer LC, Schoppet M: Osteoprotegerin: a link in between osteoporosis and arterial calcification? Lancet 2001, 358(9278):257?59. Park JK, Rosen A, Saffitz JE, Asimaki A, Litovsky SH, Mackey-Bojack SM, Halushka MK: Expression of cathepsin K and tartrate-resistant acid phosphatase will not be confined to osteoclasts but is really a general feature of multinucleated giant cells: systematic evaluation. Rheumatology 2013, 52(8):1529?533. Neven E, Persy V, Dauwe S, Schutter TD, Broe MED, D’Haese Pc: Chondrocyte in lieu of osteoblast conversion of vascular cells underlies medial calcification in uremic rats. Arterioscler Thromb Vasc Biol 2010, 30(9):1741?750. Cost P, Roublick A, Williamson M: Artery calcification in uremic rats is elevated by a low protein diet regime and prevented by remedy with ibandronate.2,2-Dimethylbut-3-ynoic acid Chemscene Kidney Int 2006, 70:1577?583.1370535-33-3 Order Speer MY, Li X, Hiremath PG, Giachelli CM: Runx2/Cbfa1, but not loss of myocardin, is necessary for smooth muscle cell lineage reprogramming toward osteochondrogenesis. J Cell Biochem 2010, 110(four):935?47. Sowa A-K, Kaiser FJ, Eckhold J, Kessler T, Aherrahrou R, Wrobel S, Kaczmarek PM, Doehring L, Schunkert H, Erdmann J, et al: Functional interaction of osteogenic transcription elements Runx2 and Vdr in transcriptional regulation of Opn during soft tissue calcification. Am J Pathol 2013, 183(1):60?eight. Komori T: Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 2006, 99(five):1233?239.PMID:35116795 Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, Chen X, Liang Y, Radcliff JS, White KE, Gattone VH: A rat model of Chronic Kidney Disease-Mineral Bone Disorder(CKD-MBD) along with the effect of dietary protein supply. Kidney Int 2009, 75(two):176?84. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, L ez-Ongil S, Coll B, Fernandez E, Valdivielso JM: RANKL increases vascular smooth muscle cell calcification via a RANK-BMP4-dependent pathway. Circ Res 2009, 104(9):1041?048. Mina H, Moronyb S, Sarosib I, Dunstanb CR, Capparellib C, Scullyb S, Vanb G, Kaufmanb S, Kostenuikb PJ, Laceyb DL, et al: Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a course of action resembling osteoclastogenesis. J Exp Med 2000, 192(4):463?74. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, Vernejoul M-C: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004, 15(7):1943?951. Collin-Osdoby P: Regulation of vascular calcification by osteoclast regulatory aspects RANKL and osteoprotegerin. Circ Res 2004, 95(11):1046?057. Byon CH, Sun Y, Chen J, Yuan K, Mao X, Heath JM, Anderson PG, Tintut Y, Demer LL, Wang D, et al: Runx2-upregulated receptor activator of nuclear factor B ligand in calcifying smooth muscle cells promotes migration and osteoclastic diffe.